Novel amplifier expression vectors producing higher levels of IL-2 led to slower tumor growth and longer survival in vivo

DNA and Cell Biology

Volumn 24, Issue 9, 2005, Pages 595-604

  Luo, Phoebe ^a,b   Tsang, T C ^a   He, X ^a   Gonzalez Pena, V ^a   Jaramillo, M ^a   Takeuchi, C ^a   Harris, D T ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 2; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; EXPRESSION VECTOR; FEMALE; GENE AMPLIFICATION; GENE CASSETTE; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VIVO STUDY; LEWIS CARCINOMA; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TRANSGENE; TUMOR GROWTH;

ANIMALS; CELL LINE, TUMOR; CYTOMEGALOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HIV LONG TERMINAL REPEAT; HUMANS; INTERLEUKIN-2; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; PROMOTER REGIONS (GENETICS); TRANSCRIPTION FACTORS; TRANSGENES;

CUCUMBER MOSAIC VIRUS;

EID: 25144484435     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2005.24.595     Document Type: Article

References (46)

1. ANDERSON, W.F. (1998). Human gene therapy. Nature 392(Suppl): 25-30.
2. AUDOUY, S.A., et al. (2002). In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm. Res. 19, 1599-1605.
3. BESSIS, N., et al. (2004). Immune responses to gene therapy vectors: Influence on vector function and effector mechanisms. Gene Ther. 11(Suppl 1), S10-S17.
4. BLAESE, R.M., et al. (1995). T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science 270, 475-480.
5. BOSHART, M., et al. (1985). A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41, 521-530.
6. BROWN, M.D., et al. (2001). Gene delivery with synthetic (non-viral) carriers. Int. J. Pharm. 229, 1-21.
7. CURIEL, D.T., et al. (2000). Progress in cancer gene therapy. Cancer Gene Ther. 7, 1197-1199.
8. DASS, C.R., et al. (2002). Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in-vivo. J. Pharm. Pharmacol. 54, 593-601.
9. DOLL, R.F., et al. (1996). Comparison of promoter strengths on gene delivery into mammalian brain cells using AAV vectors. Gene Ther. 3, 437-447.
10. DOBBELSTEIN, M. (2003). Viruses in therapy-Royal road or dead end? Virus Res. 92, 219-221.
11. DUNUSSI-JOANNOPOULOS, K., et al. (1999). Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. Blood 94, 4263-4273.
12. EMERMAN, M., et al. (1987). The specificity of the human immunodeficiency virus type 2 transactivator is different from that of human immunodeficiency virus type 1. EMBO J. 6, 3755-3760.
13. GARCIA-MARTINEZ, L.F., et al. (1995). Tat functions to stimulate the elongation properties of transcription complexes paused by the duplicated TAR RNA element of human immunodeficiency virus 2. J. Mol. Biol. 254, 350-363.
14. HARTIKKA, J, et al. (1996). An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum. Gene Ther. 7, 1205-1217.
15. HELLER, R., et al. (2001). Intradermal delivery of interleukin-12 plasmid DNA by in vivo electroporation. DNA Cell Biol. 20, 21-26.
16. HELLGREN, I., et al.(2000). Highly efficient cell-mediated gene transfer using non-viral vectors and FuGene6: In vitro and in vivo studies. Cell Mol. Life Sci. 57, 1326-1333.
17. HIRKO, A. (2003). Cationic lipid vectors for plasmid DNA delivery. Curr. Med. Chem. 10, 1185-1193.
18. KINOSHITA, Y., et al. (2001). Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells. J. Immunother. 24, 205-211.
19. KIRCHEIS, R., et al. (1998). Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2 + IFN-gamma. Cytokines Cell Mol Ther. 4, 95-103.
20. LI, S. (2004). Electroporation gene therapy: New developments in vivo and in vitro. Curr. Gene Ther. 4, 309-316.
21. LIU, Q., et al. (2003). Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther. 10, 935-940.
22. LOISEL, S., et al. (2001). Contribution of plasmid DNA to hepatotoxicity after systemic administration of lipoplexes. Hum. Gene Ther. 12, 685-696.
23. LOLLO, C.P., et al. (2000). Obstacles and advances in non-viral gene delivery. Curr. Opin. Mol. Ther. 2, 136-142.
24. LUO, P., et al. (2002). High-efficiency cloning system for versatile adaptation of DNA fragments. Biotechniques 33, 738, 740, 742.
25. LUO, P., et al. (2004). A novel inducible amplifier expression vector for high and controlled gene expression. Int. J. Mol. Med. 13, 319-325.
26. MA, H., et al. (2001). Nonviral gene therapy and its delivery systems. Curr. Pharm. Biotechnol. 2, 1-17.
27. MARSHALL, E. (1995). Gene therapy's growing pains. Science 269, 1050, 1052-1055.
28. MARTINIUK, F., et al. (2002). Helios gene gun particle delivery for therapy of acid maltase deficiency. DNA Cell Biol. 21, 717-725.
29. MEYER, F., et al. (2001). Gene therapy: Progress and challenges. Cell Mol. Biol. 47, 1277-1294.
30. MILLER, A.D. (2003). The problem with cationic liposome/micelle-based non-viral vector systems for gene therapy. Curr. Med. Chem. 10, 1195-1211.
31. NATHWANI, A.C., et al. (2003). Current status of gene therapy for hemophilia. Curr. Hematol. Rep. 2, 319-327.
32. OCHSENBEIN, A.F. (2002). Principles of tumor immunosurveillance and implications for immunotherapy. Cancer Gene Ther. 9, 1043-1055.
33. PALMER, D.H., et al. (2002). Clinical experience with adenovirus in cancer therapy. Curr. Opin. Mol. Ther. 4, 423-434.
34. PANELLI, M.C., et al. (1996). Interferon gamma (IFNgamma) gene transfer of an EMT6 tumor that is poorly responsive to IFNgamma stimulation: Increase in tumor immunogenicity is accompanied by induction of a mouse class II transactivator and class II MHC. Cancer Immunol. Immunother. 42, 99-107.
35. ROCBLITZ, C.F. (2001). Gene therapy of cancer. SWISS Med. Wkly. 131, 4-9.
36. RUBANYI, G.M. (2001). The future of human gene therapy. Mol. Aspects Med. 22, 113-142.
37. SMYTH, N. (2002). Liposomal delivery of nucleic acids in vivo. DNA Cell Biol. 21, 857-867.
38. TONG-STARKSEN, S.E., et al. (1990). Differences in transcriptional enhancers of HIV-1 and HIV-2. Response to T cell activation signals. J. Immunol. 145, 4348-4354.
39. TOUSIGNANT, J.D., et al. (2000). Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum. Gene Ther. 11, 2493-2513.
40. TSANG, T.C., et al. (1996). Simple method for adapting DNA fragments and PCR products to all of the commonly used restriction sites. Biotechniques 20, 51-52.
41. TSANG, T.C., et al. (2000). Construction of new amplifier expression vectors for high levels of IL-2 gene expression. Int. J. Mol. Med. 5, 295-300.
42. VERMA, I.M., et al. (1997). Gene therapy-Promises, problems and prospects. Nature 389, 239-242.
43. VEELKEN, H., et al. (1998). Enhancement of a constitutively active promoter for gene therapy by a positive feed-back transcriptional activator mechanism. Int. J. Mol. Med. 2, 423-428.
44. WALLER, E.K., et al. (2003). Modulation of antitumor immune responses by hematopoietic cytokines. Cancer 97, 1797-1809.
45. WELLS, D.J. (2004). Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther. 11, 1363-1369.
46. YOU, J., et al. (1999). Enhancement of transfection efficiency by protamine in DDAB lipid vesicle-mediated gene transfer. J. Biochem. (Tokyo) 125, 1160-1167.